146 related articles for article (PubMed ID: 6808457)
1. Hexamethylmelamine and hexamethylmelamine hydrochloride.
van de Vaart-van Zutphen HP; Smulders CF; Renema J; Hulshoff A
Pharm Weekbl Sci; 1982 Apr; 4(2):25-31. PubMed ID: 6808457
[TBL] [Abstract][Full Text] [Related]
2. [Hexamethylmelamine (Hexastat)].
Aabo K; Lund B
Ugeskr Laeger; 1984 Jan; 146(4):285-6. PubMed ID: 6422601
[No Abstract] [Full Text] [Related]
3. Hexamethylmelamine tissue concentrations in pelvic cancer patients.
D'Incalci M; Farina P; Sessa C; Erba E; Madonna R; Mangioni C
Ther Drug Monit; 1980; 2(2):187-8. PubMed ID: 6820202
[No Abstract] [Full Text] [Related]
4. Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography.
Ames MM; Powis G
J Chromatogr; 1979 Jun; 174(1):245-9. PubMed ID: 121123
[No Abstract] [Full Text] [Related]
5. Parenteral formulation of hexamethylmelamine potentially suitable for use in man.
Ames MM; Kovach JS
Cancer Treat Rep; 1982 Jul; 66(7):1579-81. PubMed ID: 6807543
[TBL] [Abstract][Full Text] [Related]
6. Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.
Miller KJ; McGovern RM; Ames MM
Cancer Chemother Pharmacol; 1985; 15(1):49-53. PubMed ID: 3924426
[TBL] [Abstract][Full Text] [Related]
7. Complexation in formulation of parenteral solutions: solubilization of the cytotoxic agent hexamethylmelamine by complexation with gentisic acid species.
Kreilgård B; Higuchi T; Repta AJ
J Pharm Sci; 1975 Nov; 64(11):1850-5. PubMed ID: 483
[TBL] [Abstract][Full Text] [Related]
8. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.
Ames MM; Richardson RL; Kovach JS; Moertel CG; O'Connell MJ
Cancer Res; 1990 Jan; 50(1):206-10. PubMed ID: 2104537
[TBL] [Abstract][Full Text] [Related]
9. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
Cumber AJ; Ross WC
Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of altretamine.
Damia G; D'Incalci M
Clin Pharmacokinet; 1995 Jun; 28(6):439-48. PubMed ID: 7656502
[TBL] [Abstract][Full Text] [Related]
11. Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.
Brindley C; Gescher A; Langdon SP; Broggini M; Colombo T; D'Incalci M
Biochem Pharmacol; 1982 Mar; 31(5):625-31. PubMed ID: 6805472
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.
Dubois J; Atassi G; Hanocq M; Abikhalil F
Cancer Chemother Pharmacol; 1986; 18(3):226-30. PubMed ID: 3100080
[TBL] [Abstract][Full Text] [Related]
13. [Structure-activity relationship of hexamethylmelamine derivatives].
Su YZ; Pan QC; Sun MZ; Ren YF
Zhongguo Yao Li Xue Bao; 1983 Dec; 4(4):276-80. PubMed ID: 6230876
[No Abstract] [Full Text] [Related]
14. In vitro studies with hexamethylmelamine.
Rutty CJ; Connors TA
Biochem Pharmacol; 1977 Dec; 26(24):2385-91. PubMed ID: 413551
[No Abstract] [Full Text] [Related]
15. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice.
Morimoto M; Green D; Rahman A; Goldin A; Schein PS
Cancer Res; 1980 Aug; 40(8 Pt 1):2762-7. PubMed ID: 6771004
[No Abstract] [Full Text] [Related]
17. Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
D'Incalci M; Erba E; Balconi G; Morasca L; Garattini S
Br J Cancer; 1980 Apr; 41(4):630-5. PubMed ID: 6770884
[TBL] [Abstract][Full Text] [Related]
18. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
Oldham DS; Wampler GL
Med Pediatr Oncol; 1983; 11(4):297-8. PubMed ID: 6310359
[TBL] [Abstract][Full Text] [Related]
20. Hexamethylmelamine: a critical review of an active drug.
Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
